ACTA MEDICINAE Speciál 2013

HEMATOONKOLOGIE Kompletní literatura

Akutní myeloidní leukemie

doc. MUDr. Marta Krejčí, Ph.D. Interní hematologická a onkologická klinika FN Brno

1 **Ráčil, Z. – Cetkovský, P. – Mayer, J., et al.**: Akutní myeloidní leukemie. In: *Postupy diagnostiky a léčby leukemií a jejich infekčních komplikací u dospělých pacientů. Doporučení CELL*. Brno, 2011, s. 9–20.

2 **Krejčí, M. – Šmardová, J. – Adam, Z.**: Akutní myeloidní leukemie. In: *Vnitřní lékařství*. Praha, Grada Publishing, 2011, s. 625–630.

3 **Dohner, H. – Estey, E. H. – Amadori, S., et al.**: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. *Blood*, 2010, 115, s. 453–474.

4 **Lee, J. H. – Joo, Y. D. – Kim, H., et al.**: A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. *Blood*, 2011, 118, s. 3832–3841.

5 **Cheson, B. D. – Bennet, J. M. – Kopecky, K. J., et al.**: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol*, 2003, 24, s. 4642–4649.

6 **Burnett, A. K. – Milligan, D. – Prentice, A. G., et al.**: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. *Cancer*, 2007, 109, s.1114–1124.

7 **Ráčil, Z. – Cetkovský, P. – Mayer, J., et al.**: Empirická antibiotická a antimykotická léčba febrilní neutropenie. In: *Postupy diagnostiky a léčby leukemií a jejich infekčních komplikací u dospělých pacientů. Doporučení CELL*. Brno, 2011, s. 117–130.

Chronická myeloidní leukemie

MUDr. Hana Klamová, CSc. Ústav hematologie a krevní transfuze, Praha

1 **Hehlmann, R. – Hochhaus, A. – Baccarani, M.**: Chronic myeloid leukaemia. *Lancet*, 2007, 370, s. 342–350.

2 **Dušek, L. – Mužík, J. – Kubásek, M., et al.:** Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, 2005, dostupný z: http://www.svod.cz.

3 **Faber, E. – Ondrák, K.**: Chronická myeloidní leukemie. Praha, Galén Publishing, 2010, s. 9–16.

4 **Faderl, S. – Talpaz, M. – Estrov, Z., et al.**: Chronic myelogenous leukemia: biology and therapy. *Ann Intern Med*, 1999, 131, s. 207–219.

5 **Faber, E.**: Chronická myeloidní leukemie. In: Mayer, J. – Starý, J., et al.: *Leukemie*. Praha, Grada Publishing, 2002, s. 300–310.

6 **Voglova, J. – Kašparová, P. – Vrbacký, F.**: Klinický obraz, diagnostika a diferenciální diagnostika. In: Faber, E. – Indrák, K. *Chronická myeloidní leukemie*. Praha, Galén Publishing, 2010, s. 51–64.

7 **Machová Poláková, K. – Zemanová, K. – Sobotková, M.**: Molekulární genetika v diagnostice a léčbě CML. *Vnitř Lék*, 2012, 58, s. 2S38–2S45.

8 **Baccarani, M. – Cortes, J. – Pane, F., et al.**: Chronic myeloid leukemia: An update concept and management recommendations of European LeukemiaNet. *J Clin Oncol*, 2009, 27, s. 6041–6051.

9 **Kantarjian, H. – Schiffer, Ch. – Jones, D., et al.**: Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. *Blood*, 2008, 111, s. 1774–1780.

10 **Tefferi, A. – Vardiman, J. W.**: Classification and diagnosis of myeloproliferatice neoplasmas: the 2008 World Health Organization kriteria nad point-of-care diagnostic algorithms. *Leukemia*, 2008, 22, s. 14–22.

11 **Kantarjian, H. M. – O'Brien, S. – Cortes, J. E., et al.**: Complete cytogenetic and molecular response to interferon-alfa-based therapy for chraonic myelogenous leukemia are associated with excellent long-term prognosis. *Cancer*, 2003, 97, s. 1033–1041.

12 **Drucker, B. J. – Tamura, S. – Buchdunger, E., et al.**: Effect of selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. *Nature Medicine*, 1996, 2, s. 561–566.

13 **Deininger, M. W. – Goldman, J. M. – Ldon, N., et al.**: The tyrosine dinase inhibitor CGP571488 selectivelyinhibits hte geowth of BCR-ABL-positive cells. *Blood*, 1997, 90, s. 3691–3698.

14 **Indrák, K. – Faber, E.**: Nilotinib. *Farmakoterapie*, 2008, 4, s. 157–163.

15 **Hochhaus, A. – Kantarjian, H. M. – Baccarani, M., et al.**: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. *Blood*, 2007, 109, s. 2303–2309.

16 **Klamová, H. – Faber, E. – Žáčková, D., et al.**: Dasatinib in imatainib-resistanto-intolerant CML patients: data from the clinical practice of 6 hematological center in the Czech Republic. *Neoplasma*, 2010, 57, s. 355–359.

17 **Kantarjian, H. – Shah, N. P. – Hochhaus, A., et al.**: Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med*, 2010, 362, s. 2260–2270.

18 **Cortes, J. E. – Kantarjian, H. M. – Brummendor, T. H., et al.**: Safety and afficacy of bosutinib (SKI-606) in chronic phase chronic Ph+ CML patients with resistence or intolerance to imatinib. *Blood*, 2011, doi:101182/blood-2011-O5-355594.

19 **Cortes, J. E. – Talpaz, M. – Bixby, D., et al.**: A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia and other hematologic malignancies. *Blood*, 2010, 116, abstrakt 210.

20 **Boccia, M. – Lauria, F.**: Immunotherapy of chronic myeloid leukemia. In: Cortes, J. – Deininger, M.: *Chronic myeloid leukemia*. New York, Informa Healthcare, 2007, s. 95–108.

21 **Klamová, H.**: *Vnitř Lék*, 2012, 58, s. 27–37.

Lymfomy jako vzácná onemocnění, jejich výskyt a problematika úhrady léčby

doc. MUDr. Samuel Vokurka, Ph.D. Hematologicko-onkologické oddělení FN Plzeň
JUDr. Ondřej Dostál, Ph.D., LL.M. Platforma zdravotních pojištěnců ČR, o. s.
MUDr. Kateřina Kubáčková Onkologická klinika FN v Motole, Praha

1 **Swerdlow, S. H. – Campo, E. – Harris, N. L., et al.**: *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition*. World Health Organization, 2008.
2 **Sant, M. – Allemani, C. – Tereanu, C., et al.**: Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. *Blood*, 2010, 116, s. 3724–3734.
3 **Papajík, T. – Trněný, M. – Vášová, I., et al.**: Epidemiologie nehodgkinových lymfomů v České republice, Evropě a Severní Americe. *Onkologie*, 2009, 3, s. 141–146.
4 Dostupné online: www.cancerresearchuk.org, vyhledáno 23. 4. 2013.
5 Dostupné online: www.rarecarenet.eu, vyhledáno 23. 4. 2013.
6 **Gatta, G. – van der Zwan, J. M. – Casali, P. G., et al**.: Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer*, 2011, 47, s. 2493–2511.
7 **Hiddemann, et al.**: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood*, 2005, 106, s. 3725–3732.
8 **Coiffier, B., et al.**: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. *Blood*, 2010, 12, s. 2040–2045.
9 **Schulz, J., at al.**: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis. *J Natl Cancer Inst*, 2007, 99, s. 706–714.
10 **Vidal, L., et al.**: Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials. *J Natl Cancer Inst*, 2009, 101, s. 248–255.
11 **Kluin-Nelemans, H. C., et al.**: Treatment of older patients with mantle-cell lymphoma. *NEJM*, 2012, 367, s. 520–531.
12 **Šálek, D. – Vášová, I. – Pytlik, R., et al.**: Mantle cell lymphoma international prognostic score is valid and confirmed in unselected cohort of patients treated in rituximab era. *Blood*, 2008, 112, ASH Annual Meeting Abstracts 3745.
13 **Smolej, L. – Vášová, I. – Šálek, D., et al.**: Diagnostic and therapeutic approach to small lymphocytic lymphoma (SLL): experience of Czech lymphoma study group. *Haematologica*, 2010, 95 (dopl. 2), s. 330.

Nové léky v hematoonkologii

PharmDr. Dana Syrová nemocniční lékárna VFN Praha, subkatedra klinické farmacie IPVZ Praha

1 **Adam, Z. – Pour, L. – Vorlíček, J. – Hájek, R. – Koptíková, J. – Šmardová, J.**: Cílená léčba v onkologii. *Remedia*, 2005, 15 (4–5), s. 390–404.
2 **Adam, Z . – Vorlíček, J. – Sedláčková, Š.**: Nová léčiva v terapii zhoubných nádorů. *Praktické lékárenství*, 2006, 2, s. 70–75.
3 **Belada, D.**: Monoklonální protilátky v léčbě lymfomů. *Remedia*, 2008, 18 (6), s. 416–423.
4 **Doubek, M. – Ráčil, Z. – Mayer, J.**: *Klinické využití humanizované monoklonální protilátky alemtuzumab*. Brno, Masarykova universita, 2006.
5 **Faber, E.**: Lékové profily – dasatinib. *Farmakoterapie*, 2006, 2, s. 135–136.
6 **Hájek, R. – Maisnar, V. – Krejčí, M.**: Thalidomid. *Klinická farmakologie a farmacie*, 2005, 19, s. 43–46.
7 **Hájek, R. – Holánek, M.**: Lenalidomid v léčbě mnohočetného myelomu. *Farmakoterapie*, 2009, 5 (2), s. 159–163.
8 **Hájek, R. – Maisnar, V. – Gregora, E.**: Moderní léčba mnohočetného myelomu. *Farmakoterapie*, 2010, 6 (2), s. 187–192.
9 **Harris, M.**: Monoclonal antibodies as therapeutic agents for cancer. *The Lancet Onkology-CZ*, 2004, 3 (3), s. 214–227.
10 **Hayden, P.J., et al.**: Novinky v léčbě mnohočetného myelomu. *Current Opinion in Hematology-CZ*, 2009, 1, s. 9–14.
11 **Indrák, K. – Faber, E.**: Lékové profily – nilotinib. *Farmakoterapie*, 2007, 2, s. 105–108.
12 **Katzung, B. G.**: Chemoterapie nádorů, Imunofarmakologie. In: *Základní a klinická farmakologie*. Jinočany, H&H, 2006, s. 871–904.
13 **Klener, P. – Klener, P., jr.**: *Nová protinádorová léčiva a léčebné strategie v onkologii*. Grada, Praha, 2010.
14 **Klener, P., at al.**: Léčba nádorových onemocnění. In: *Vnitřní lékařství*. Praha, Galén, 2001, s. 34–43.
15 **Klener, P.**: Protinádorová chemoterapie pro 21. století. *Klinická onkologie*, 2003, 16 (6), s. 243–248.
16 **Mayer, J. – Doubek, M. – Brychtová, Y. – Vorlíček, J.**: Využití rituximabu v léčbě chronické myeloidní leukemie. *Klinická onkologie*, 2003, 16 (6), s. 178–183.
17 **Mayer, J.**: Klinické využití monoklonální protilátky rituximab. Brno, Masarykova univerzita, 2004.
18 **Papajík, T. – Faber, E. – Indrák, K.**: Nové směry a perspektivy v léčbě hematologických malignit. *Interní medicína pro praxi*, 2003, 2, s. 71–77.
19 **Slíva, J.**: Záhadné „maby", „niby" a „miby". *New EU Magazine of Medicine*, 2007, 4, s. 17–18.
20 **Schering, s. r. o.**: *Zevalin. Produktová monografie zevalin*.
21 **Smolej, L.**: Současné možnosti léčby chronické lymfocytární leukemie. *Remedia*, 2010, 20 (1), s. 39–47.
22 **Špička, I., at al.**: Terapie mnohočetného myelomu. In: *Mnohočetný myelom a další monoklonální gamapatie*. Galén, 2005, s. 71–95.
23 **Špička, I. – Kleibl, Z. – Hájek, R.**: *Lékové profily – bortezomid*. Remedia, 2005, 15 (3), s. 196–203.

Antimykotická profylaxe u nemocných s hematologickými malignitami

prof. MUDr. Petr Sedláček, CSc. Klinika dětské hematologie a onkologie, FN v Motole a 2. LF UK v Praze
MUDr. Vanda Chrenková Ústav lékařské mikrobiologie, FN v Motole a 2. LF UK v Praze
MUDr. Petra Keslová | MUDr. Daniela Janečková | MUDr. Petr Říha
Klinika dětské hematologie a onkologie, FN v Motole, Praha
MUDr. Lucie Šrámková, Ph.D. Klinika dětské hematologie a onkologie, FN v Motole a 2. LF UK v Praze

1 **Zhang, P., et al.**: Risk factors and prognosis of invasive fungal infections in allogeneic stem cell transplantation recipients: a single-institution experience. *Transplant infectious disease: an official journal of the Transplantation Society*, 2010, 12, s. 316–321, doi: 10.1111/j.1399–3062.2010.00497.
2 **Richardson, M. – Lass-Florl, C.**: Changing epidemiology of systemic fungal infections. *Clin Microbiol Infect*, 2008, 14, s. 5–24, doi: 10.1111/j.1469–0691.2008.01978.
3 **Kurosawa, M., et al.**: Epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. *Int J Hematol*, 2012, 96, s. 748–757, doi: 10.1007/s12185-012-1210-y.
4 **Asano-Mori, Y.**: Fungal infections after hematopoietic stem cell transplantation. *Int J Hematol*, 2010, 91, s. 576–587, doi: 10.1007/s12185-010-0574-0.
5 **Marr, K. A.**: Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. *Curr Opin Infect Dis*, 2008, 21, s. 409–414, doi: 10.1097/QCO.0b013e328307c7d9.
6 **Vazquez, L., et al.**: Antifungal prophylaxis in the haematological patient: a practical approach. *Rev Esp Quimioter*, 2012, 25, s. 299–304.
7 **Maertens, J., et al.**: European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. *Bone Marrow Transplantation*, 2011, 46, s. 709–718, doi: 10.1038/bmt.2010.175.
8 **Sautour, M., et al.**: A prospective survey of air and surface fungal contamination in a medical mycology laboratory at a tertiary care university hospital. *Am J Infect Control*, 2009, 37, s. 189–194, doi: 10.1016/j.ajic.2008.06.009.
9 **Chrenkova, V., et al.**: [Invasive mucormycosis in pediatric hematology patients—single-center experience from 2005–2010]. *Klin Mikrobiol Infekc Lek*, 2012, 18, s. 102–108.
10 **Lehrnbecher, T. – Laws, H. J.**: [Infectious complications in pediatric cancer patients]. *Klin Padiatr*, 2005, 217, s. S3–8, doi: 10.1055/s-2005-872498.
11 **Baskova, L. – Buchta, V.**: Laboratory diagnostics of invasive fungal infections: an overview with emphasis on molecular approach. *Folia Microbiol (Praha)*, 2012, 57, s. 421–430, doi: 10.1007/s12223-012-0152-3.
12 **McCulloch, E., et al.**: Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. *J Clin Pathol*, 2012, 65, s. 83–86, doi: 10.1136/jcp.2011.090464.
13 **Kourkoumpetis, T. K. – Fuchs, B. B. – Coleman, J. J. – Desalermos, A. – Mylonakis, E.**: Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. *Clin Infect Dis*, 2012, 54, s. 1322–1331, doi: 10.1093/cid/cis132.
14 **Arda, B., et al.**: [Mucormycosis: retrospective evaluation of 12 cases]. *Mikrobiyol Bul*, 2011, 45, s. 504–511.
15 **Nebiker, C. A., et al.**: Lung resection in hematologic patients with pulmonary invasive fungal disease. *Chest*, 2012, 142, s. 988–995, doi: 10.1378/chest.11-1964.
16 **Nucci, M. – Perfect, J. R.**: When primary antifungal therapy fails. *Clin Infect Dis*, 2008, 46, s. 1426–1433, doi: 10.1086/587101.
17 **Rafiei, A. – Amirrajab, N.**: Fungal contamination of indoor public swimming pools, Ahwaz, south-west of Iran. *Iran J Public Health*, 2010, 39, s. 124–128.
18 **Fletcher, J. – Leach, J. E. – Eversole, K. – Tauxe, R.**: Human pathogens on plants: designing a multidisciplinary strategy for research. *Phytopathology*, 2013, 103, s. 306–315, doi: 10.1094/PHYTO-09-12-0236-IA.
19 **Mank, A. P. – Davies, M.**: Examining low bacterial dietary practice: a survey on low bacterial food. *Eur J Oncol Nurs*, 2008, 12, s. 342–348, doi: 10.1016/j.ejon.2008.03.005.
20 **Slavin, M. A., et al.**: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study. *J Infect Dis*, 1995, 171, s. 1545–1552.
21 **Ananda-Rajah, M. R., et al.**: Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. *Haematologica*, 2012, 97, s. 459–463, doi: 10.3324/haematol.2011.051995.
22 **Cornely, O. A., et al.**: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med*, 2007, 356, s. 348–359, doi: 10.1056/NEJMoa061094.
23 **Racil, Z., et al.**: Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics. *Leukemia & lymphoma*, 2012, doi: 10.3109/10428194.2012.729057.
24 **Xu, S. X. – Shen, J. L. – Tang, X. F. – Feng, B.**: Newer antifungal agents for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis. *Transplant Proc*, 2013, 45, s. 407–414, doi: 10.1016/j.transproceed.2012.07.149.
25 **Petrikkos, G. – Skiada, A.**: Recent advances in antifungal chemotherapy. *Int J Antimicrob Agents*, 2007, 30, s. 108–117, doi: 10.1016/j.ijantimicag.2007.03.009.
26 **Marks, D. I., et al.**: Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. *Br J Haematol*, 2011, 155, s. 318–327, doi: 10.1111/j.1365-2141.2011.08838.x.
27 **Sanchez-Ortega, I., et al.**: Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. *Bone Marrow Transplantation*, 2011, 46, s. 733–739, doi: 10.1038/bmt.2010.185.
28 **Ullmann, A. J., et al.:** ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). *Clin Microbiol Infect*, 2012, 18, s. 53–67, doi: 10.1111/1469-0691.12041.
29 **Moriyama, B., et al.**: Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. *Mycoses*, 2012, 55, s. 290–297, doi: 10.1111/j.1439-0507.2011.02158.x.
30 **Nivoix, Y. – Ubeaud-Sequier, G. – Engel, P. – Leveque, D. – Herbrecht, R.**: Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. *Curr Drug Metab*, 2009, 10, s. 395–409.
31 **Gubbins, P. O.**: Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients. *Curr Opin Infect Dis*, 2007, 20, s. 579–586, doi: 10.1097/QCO.0b013e3282f1be91.
32 **Leleu, C., et al.**: Efficacy of liposomal amphotericin B for prophylaxis of acute or reactivation models of invasive pulmonary aspergillosis.

Mycoses, 2012, doi: 10.1111/myc.12011.
33 **Cateau, E. – Berjeaud, J. M. – Imbert, C.**: Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. *Int J Antimicrob Agents*, 2011, 37, s. 380–384, doi: 10.1016/j.ijantimicag.2010.12.016.
34 **Cordonnier, C., et al.**: Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. *Haematologica*, 2010, 95, s. 1762–1768, doi: 10.3324/haematol.2009.020073.
35 **Masamoto, Y. – Nannya, Y. – Kurokawa, M.**: Voriconazole is effective as secondary antifungal prophylaxis in leukemia patients with prior pulmonary fungal disease: case series and review of literature. *Journal of Chemotherapy*, 2011, 23, s. 17–23.
36 **Liu, F., et al.**: Risk factors for recurrence of invasive fungal infection during secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Transplant infectious disease: an official journal of the Transplantation Society, 2013, doi: 10.1111/tid.12068.
37 **Rogers, T. R. – Slavin, M. A. – Donnelly, J. P.**: Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? *Br J Haematol*, 2011, 153, s. 681–697, doi: 10.1111/j.1365-2141.2011.08650.x.
38 **Marchetti, O., et al.**: ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. *Bone Marrow Transplantation*, 2012, 47, s. 846–854, doi: 10.1038/bmt.2011.178.

Cílená terapie B-lymfoproliferací

doc. MUDr. Andrea Janíková, Ph.D.
Interní hematologická a onkologická klinika, FN Brno a LF MU Brno

1 **Abukhdeir, A. M. – Park, B. H.**: P21 and p27: roles in carcinomagenesis and drug resistence. *Expert Rev Mol Med*, 2008, 10, s. 19.
2 **Ansell, S. M. – Tang, H. – Kurtin, P. J., et al.**: Temsirolimus and rituximab in patiens with relapsed or refractory mantle cell lymphoma a phase 2 study. *Lancet Oncol*, 2011, 12, s. 361–368.
3 **Ansell, S. M. – Inwards, D. J. – Rolland, K. M., et al.**: Low-dose single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. *Cancer*, 2008, 113, s. 508–514.
4 **Bedford, I. – Lowe, J. – Dick, L. R., et al.**: Ubiquitin-like protein conjugation and ubiquitin-proteasome system as drug targets. *Nat Rev Drug Discov*, 2011, 10, s. 29–46.
5 **Dal Porto, J. M. – Gauld, S. B. – Merrel, K. T., et al.**: B cell antigen receptor signaling 101. *Mol Immunol*, 2004, 41, s. 599–613.
6 **Fisher, R. I. – Bernstein, S. H. – Kahl, B. S., et al.**: Multicenter phase II study of bortezomib in patiens with relapsed or refractory mantle cell lymphoma. *J Clin Oncol*, 2006, 24, s. 4867–4874.
7 **Gold, M. R.**: B cell receptor signaling. *Cell signaling technology*, 2010, http: www.cellsignal.com.
8 **Goy, A.**: Phase II Study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin´s lymphoma. *J Clin Oncol*, 2005, 23, s. 667–675.
9 **Goy, A. – Bernstein, S. H. – McDonald, A., et al.**: Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase II PINNACLE trial. *Leuk Lymphoma*, 2010, 21, s. 1756–1764.
10 **Habermann, T. M. – Lossos, I. S. – Justice, G., et al.**: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. *Br J Hematol*, 2009, 145, s. 344–349.
11 **Harwood, N. E. – Batista, F. D.**: New insights into the early molecular events underlying B cell activation. *Imunity*, 2008, 28, s. 609–619.
12 **Harwood, N. E. – Batista, F. D.**: Early events in B cell activation. *Ann Rev Immunol*, 2010, 28, s. 185–210.
13 **Hess, G. – Herbrecht, R. – Romaguera, J., et al.**: Phase III study to evaluace temsirolimus compared with investigator´s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. *J Clin Oncol*, 2009, 27, s. 3822–3829.
14 **Hideshima, T. – Chauhan, D. – Richardson, P., et al.**: NF-kappa B as a therapeutic target in multiple myeloma. *J Biol Chem*, 2002, 277, s. 16639–16647.
15 **Jagannath, S. – Barlogie, B. – Berenson, J., et al.**: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. *Br J Hematol*, 2004, 127, s. 165–172.
16 **Kurosaki, T. – Shinohara, H. – Baba, Y.**: B cell signaling and fate decision. *Annu Rev Immunol*, 2010, 28, s. 21–55.
17 **Lam, L. T. – Davis, R. E. – Pierce, J., et al.**: Small molecule inhibitors of IKappa B kinase are selectively toxic for subgroup of difuse large B-cell lymphoma defined by gene expression profilig. *Clin Cancer Res*, 2005, 11, s. 28–40.
18 **Martin, P. – Chadburn, A. – Christos, P., et al.**: Intensive treatment strategies may not provide superior outcome in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. *Ann Oncol*, 2008, 19, s. 1327–1330.
19 **Richardson, P. G. – Barlogie, B. – Berenson, J., et al.**: A phase 2 study of bortezomib in relapsed, refractory myeloma. *N Engl J Med*, 2003, 348, s. 2609–2617.
20 **Richardson, P. G. – Sonneveld, P. – Schuster, M. W., et al.**: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *N Engl J Med*, 2005, 352, s. 2487–2498.
21 **Rizzatti, E. G. – Falcao, R. P. – Panepucci, R. A., et al.**: Gene expression profilig of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signaling pathways. *Br J Haematol*, 2005, 130, s. 516–526.
22 **Roschewski, M. – Dunleavy, K. – Wilson, H. W.**: Diffuse large B cell lymphoma: molecular targeted therapy. *Int J Hematom*, 2012, publikováno on-line.
23 **San Miguel, J. F. – Schlag, R. – Khueageva, N. K., et al.**: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med*, 2008, 359, s. 906–917.
24 **Schwartz, A. L. – Ciechanover, A.**: The ubiquitin-proteasome pathway and pathogenesis of human diseases. *Annu Rev Med*, 1999, 50, s. 57–74.
25 **Strauss, S. J. – Higginbottom, K. – Jupiter, S., et al.**: The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B cell lymphoma cell lines. *Cancer Res*, 2007, 67, s. 2783–2790.
26 **Wang, M. – Fayad, L. – Wagner-Bartak, N., et al.**: Lenalidomide in combination with rituximab for patiens with relapsed or refraktory mantle-cell lymphoma: a phase 1/2clinical trial. *Lancet Oncol*, 13, s. 716–723.
27 **Witzig, T. E. – Vose, J. M. – Zinzani, P. L., et al.**: An international phase II trial of single-agent lenalidomide relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. *Ann Oncol*, 2011, 22, s. 1622–1627.
28 **Zaja, F. – De Luca, S. – Vitolo, U., et al.**: Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. *Hematologova*, 2012, 97, s. 416–422.

Maligní lymfomy: agresivní non-hodgkinské lymfomy B linie

doc. MUDr. Martin Klabusay, Ph.D. Integrované centrum celulární terapie a regenerativní medicíny, Mezinárodní centrum klinického výzkumu, FNUSA, Brno, Hemato-onkologická klinika LF UP, Olomouc

1 **Staudt, L. M. – Connors, J. M. – Armitage, J. O. – Chan, W. C. – Pedro Farinha, P. – Smith, L. M. – Falini, B. – Banham, A. H. – Rosenwald, A. – Ott, G. – Miller-Hermelink, H. K. – Campo, E. – Braziel, R. M. – Jaffe, E. S. – Hans, Z. Ch. P. – Weisenburger, D. D. – Greiner, T. C. – Gascoyne, R. D. – Delabie, J.**: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*, 2004, 103, s. 275–282.

2 **Campo, E. – Swerdlow, S. H. – Harris, N. L. – Pileri, S. – Stein, H. – Jaffe, E. S.**: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood*, 2011, 117, s. 5019–5032.

3 **Morgan, E. A. – Nascimento, A. F.**: Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. *Advances in Hematology*, 2012, ID 529572, s. 6, doi: 10.1155/2012/529572.

4 **Loong, F. – Chan, A. C. L. – Ho, B. C. S. – Chau, Y.-P. – Lee, H.-Y. – Cheuk, W. – Yuen, W.-K. – Ng, W.-S. – Cheung, H.-L. – John, K. C. – Chan, J. K. C.**: Diffuse large B-cell lymphoma associated with chronic inflammation as an incidental finding and new clinical scenarios. *Modern Pathology*, 2010, 23, s. 493–501.

5 **Castillo, J. J. – John, L. – Reagan, J. L.**: Plasmablastic lymphoma: A systematic review. *The Scientific World JOURNAL*, 2011, 11, s. 687–696.

6 **Mauch, P. M. – Armitage, J. O. – Coiffier, B. – Dalla-Favera, L. – Harris, N. L.**: *Non-hodgkin's lymphomas*. Eds., Lippincott Williams & Wilkins, 2004.

Specifická lymfoproliferace zvaná Hodgkinův lymfom

MUDr. Luděk Raida, Ph.D. Hemato-onkologická klinika LF UP a FN Olomouc

1 **Jaffe, E. S. – Harris, N. L. – Stein, H., et al.**: Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, Francie: IARC Press, 2001.

2 **Rosenberg, S. A. – Boiron, M. – De Vita, V. T., et al.**: Report of the committee on Hodgkin's disease staging procedures. *Cancer Res*, 1971, 31, s. 1862.

3 **Lister, T. A. – Brother, D. – Sutcliffe, S. B., et al.**: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. *J Clin Oncol*, 1989, 7, s. 1630–1636.

4 **Connors, J. M.**: Lymphocyte-predominant Hodgkin's lymphoma. *American Society of Hematology Education Program Book*, 2001, s. 187–190.

5 **Schulz, H. – Rehwald, U. – Morschhauser, F., et al.**: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). *Blood*, 2008, 111, s. 109–111.

6 **Bonadonna, G. – Bonfante, V. – Viviani, S., et al.**: ABVD plus subtotal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. *J Clin Oncol*, 2004, 22, s. 2835–2841.

7 **Engert, A. – Schiller, P. – Josting, A., et al.**: Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. *J Clin Oncol*, 2003, 21, s. 3601–3608.

8 **Dugan, D. B. – Petroni, G. R. – Johnson, J. L., et al.**: Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. *J Clin Oncol*, 2003, 21, s. 607–614.

9 **Hornig, S. J. – Hoppe, R. T. – Breslin, S., et al.**: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. *J Clin Oncol*, 2002, 20, s. 630–637.

10 **Gobbi, P. G. – Levis, A. – Chisesi, T., et al.**: ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. *J Clin Oncol*, 2005, 23, s. 9198–9207.

11 **Diehl, V. – Franklin, J. – Pfreundschuch, M., et al.**: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. *N Engl J Med*, 2003, 348, s. 2386–2395.

12 **Diehl, V. – Haverkamp, H. – Mueller, R. P., et al.**: Eight cycles of BEACOPP escalated compared with 4 cycles of BEACOPP escalated followed by 4 cycles of BEACOPP baseline with or without radiotherapy in patients in advanced stage Hodgkin lymphoma (HL): final analysis of the randomized HD12 trial of the German Hodgkin Study Group (GHSG) (abstract). *Blood*, 2008, 112, s. 1558.

13 **Aleman, B. M. – Raemaekers, J. M. – Tomisic, R., et al.**: Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys*, 2007, 67, s. 19–30.

14 **Kobe, C. – Dietlein, M. – Franclin, J., et al.**: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. *Blood*, 2008, 112, s. 3989–3994.

15 **Ruffer, J. U. – Ballova, V. – Glossmann, J., et al.**: BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkin's disease—results of the German Hodgkin Study Group. *Leuk Lymphoma*, 2005, 46, s. 1561–1567.

16 **Linch, D. C. – Winfield, D. – Goldstone, A. H., et al.**: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of BNLI randomised trial. *Lancet*, 1993, 34, s. 1051–1054.

17 **Schmitz, N. – Pfistner, B. – Sextro, M., et al.**: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. *Lancet*, 2002, 359, s. 2065–2071.

18 **Sureda, A. – Robinson, S. – Canals, C., et al.**: Reduced-intensity conditioning compared with conventional allogenic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol*, 2008, 26, s. 455–462.

19 **Younes, A. – Gopal, A. K. – Smith, S. E., et al.**: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol*, 2012, 30, s. 2183–2189.

Mnohočetný myelom

prof. MUDr. Roman Hájek, CSc. | MUDr. Hana Plonková | MUDr. Tomáš Jelínek
Klinika hematoonkologie, FN Ostrava a LF Ostravské univerzity

1 **San-Miguel, J. F. – Dimopoulos, M. A. – Stadtmauer, E. A., et al.**: Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide anddexamethasone. *Clin Lymphoma Myeloma Leuk*, 2011, 11 (1), s. 38–43.

2 **Palumbo, A. – Bringhen, S. – Liberati, A. M., et al.**: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. *Blood*, 2008, 15, 112 (8), s. 3107–3114.

3 **Hájek, R., et al.**: Diagnostika a léčba mnohočetného myelomu. Doporučení vypracované Českou myelomovou skupinou, Myelomovou sekcí ČHS a Slovenskou myelomovou společností pro diagnostiku a léčbu mnohočetného myelomu. *Transfuze a hematologie dnes*, 2012, s. 1–92.

4 **Fayers, P. M. – Palumbo, A. – Hulin, C., et al.**: Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. *Blood*, 2011, 118 (5), s. 1239–1247.

5 **Kapoor, P. – Rajkumar, S. V. – Dispenzieri, A., et al.**: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. *Leukemia*, 2011, 25 (4), s. 689–696.

6 **Morgan, G. J. – Davies, F.E. – Gregory, W. M., et al.**: Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. *Blood*, 2011, 118 (5), s. 1231–1238.

7 **Lokhorst, H. M. – Breitkreuz, B. – van der Holt, E., et al.**: First intermin analysis of the joint HOVON-50/GMMG-HD3 randomized study effect of thalidomide combined with adriamycin, dexamethasone and HD melphalan in patients wit multiple myeloma. *Haematologica*, 2005, 90, dopl. 1, PL10.06.

8 **Morgan, G. J. – Davies, F. E. – Gregory, W. M., et al.**: Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. *Haematologica*, 2012, 97 (3), s. 442–450.

9 **Ludwig, H. – Durie, B. G. – McCarthy, P., et al.**: IMWG consensus on maintenance therapy in multiple myeloma. *Blood*, 2012, 119 (13), s. 3003–3015.

10 **Dimopoulos, M. – Spencer, A. – Attal, M., et al.**: Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. *N Engl J Med*, 2007, 357 (21), s. 2123–2132.

11 **Weber, D. M. – Chen, C. – Niesvizky, R., et al.**: Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. *N Engl J Med*, 2007, 357, s. 2133–2142.

12 **Palumbo, A. – Anderson, K.**: Multiple myeloma. *N Engl J Med*, 2011, 364 (11), s. 1046–1060.

13 **McCarthy, P. – Lazar, K. – Anderson, K., et al.**: Phase III intergroup study of lenalidomide versus placebo maintanance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALB ECOG BMT-CTN 100104. *Haematologica*, 2011, 96 (s1), s. S23-S24.

14 **Attal, M. – Olivier, P. – Cannes Lauwers, V., et al.**: Maintenance treatment with lenalidomide after transplantation for myeloma: analysis fo secondary malignancies within the IFM 2005-02 trial. *Haematologica*, 2011, 96 (s1), s. S23.

15 **Palumbo, A. – Adam, Z. – Kropff, M., et al.**: A phase 3 study evaluating the eficacy and safety of lenalidomide (len) combined with melphalan and prednisone folowed by continoues lenalidomide maintenance (MPR-R) in patients ≥ 65 years (yrs) with newly diagnosed multiple myeloma (NDMM): Updated results from pts aged 65—75 yrs enrolled in MM-015. *Blood (ASH Annual meetings abstract)*, 2011, 118 (21), abstrakt, s. 475.

16 **San Miguel, J. F. – Schlag, R. – Khuageva, N. K., et al.**: VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med*, 2008, 359 (9), s. 906–917.

17 **Harousseau, J. L. – Attal, M. – Avet-Loiseau, H. – Marit, G., et al.**: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. *J Clin Oncol*, 2010, 28 (30), s. 4621–4629.

18 **Cavo, M. – Pantani, L. – Patriarca, F., et al.**: Superior complete response rate (CR) and progression-free surfoval (PFS) with bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as consolidation therapy after autologus stem-cell transplantation (ASCT in multiple myeloma (MM). *Blood (ASH Annual Meeting Abstracts)*, 2011, 118, s. 1871.

19 **Mellqvist, U. H. – Gimsing, P. – Hjertner, O., et al.**: Improved progression free surfoval with bortezomib consolidation after high dose melphalan; results of a randomized phase III trial. *Haematologica*, 2011, 96 (s1), s. S31 (a. O–11).

20 **Mateos, M. V. – Oriol, A. – Teruel, A. I., et al.**: Maintenance therapy with bortezomib plus thalidomide (VT) or bortezomib plus prednisone (VP) in elderly myeloma patiens included in the GEM2005MAS65 spanish randomized trial. *Blood (ASH Annual Meeting Abstracts)*, 2011, 118, s. 477.

21 **Sonnenveld, P. – van der Holt, B. – Schmidt-Wolf, I. G. H., et al.**: First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs. VAD as induction treatment prior to high dose melphalan (HDM) in patiens with newly diagnose multiple myeloma (MM). *Haematologica*, 2009, 94 (s2), s. 473.